Oncobiologics (NASDAQ: ONS) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.
Volatility & Risk
Oncobiologics has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Organovo has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500.
This table compares Oncobiologics and Organovo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Oncobiologics and Organovo’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Oncobiologics||$3.81 million||7.71||-$38.84 million||N/A||N/A|
|Organovo||$4.23 million||35.64||-$38.44 million||($0.38)||-3.71|
Organovo has higher revenue and earnings than Oncobiologics.
Insider and Institutional Ownership
17.9% of Oncobiologics shares are held by institutional investors. Comparatively, 25.8% of Organovo shares are held by institutional investors. 33.5% of Oncobiologics shares are held by insiders. Comparatively, 10.2% of Organovo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Oncobiologics and Organovo, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Oncobiologics presently has a consensus target price of $9.00, suggesting a potential upside of 682.61%. Organovo has a consensus target price of $3.94, suggesting a potential upside of 179.26%. Given Oncobiologics’ higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Organovo.
Organovo beats Oncobiologics on 9 of the 12 factors compared between the two stocks.
Oncobiologics Company Profile
Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).
Organovo Company Profile
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.